Department of Pathology, University of California San Francisco, San Francisco, CA 94143-0506, USA.
J Immunol. 2010 Dec 1;185(11):6426-30. doi: 10.4049/jimmunol.0903940. Epub 2010 Oct 29.
IL-2 controls the survival of regulatory T cells (Tregs), but it is unclear whether IL-2 also directly affects Treg suppressive capacity in vivo. We have found that eliminating Bim-dependent apoptosis in IL-2- and CD25-deficient mice restored Treg numbers but failed to cure their lethal autoimmune disease, demonstrating that IL-2-dependent survival and suppressive activity can be uncoupled in Tregs. Treatment with IL-2-anti-IL-2-Ab complexes enhanced the numbers and suppressive capacity of IL-2-deprived Tregs with striking increases in CD25, CTLA-4, and CD39/CD73 expression. Although cytokine treatment induced these suppressive mechanisms in both IL-2(-/-) and IL-2(-/-)Bim(-/-) mice, it only reversed autoimmune disease in the latter. Our results suggest that successful IL-2 therapy of established autoimmune diseases will require a threshold quantity of Tregs present at the start of treatment and show that the suppressive capacity of Tregs critically depends on IL-2 even when Treg survival is independent of this cytokine.
IL-2 控制调节性 T 细胞(Tregs)的存活,但尚不清楚 IL-2 是否也直接影响体内 Treg 的抑制能力。我们发现,消除 IL-2 和 CD25 缺陷小鼠中 Bim 依赖性凋亡恢复了 Treg 数量,但未能治愈其致命的自身免疫性疾病,表明 IL-2 依赖性存活和抑制活性可在 Tregs 中分离。用 IL-2-抗 IL-2-Ab 复合物治疗可增强 IL-2 剥夺的 Tregs 的数量和抑制能力,CD25、CTLA-4 和 CD39/CD73 的表达显著增加。尽管细胞因子治疗在 IL-2(-/-)和 IL-2(-/-)Bim(-/-)小鼠中诱导了这些抑制机制,但仅在后一种情况下逆转了自身免疫性疾病。我们的结果表明,成功治疗已建立的自身免疫性疾病将需要在治疗开始时存在一定数量的 Tregs,并且表明 Treg 的抑制能力严重依赖于 IL-2,即使 Treg 的存活与这种细胞因子无关。